Introduction and Objective: Polygenic risk scores (PRS) are emerging as a novel tool for prevention and management of cardio-renal-metabolic (CRM) disease. In this study, we describe results from the first year of implementing clinical PRS testing for CRM disease in a large community health system.Methods: CLIA-certified PRS testing for type 1 diabetes, type 2 diabetes, obesity, chronic kidney disease, and coronary artery disease was implemented at Endeavor Health. Patient/clinician characteristics and impact on clinical decisions was analyzed using retrospective chart review and descriptive statistics.Results: Of 153 patients with PRS testing, 66% were male, 12% non-white, 5% Hispanic, 25% with diabetes, and 31% with heart disease. Mean age was 54 ±13 years, HbA1c 5.8 ±0.7%, LDL 104.6±40.3 mg/dL and eGFR 89 ±17 mL/min. Clinicians ordering PRS (n=33) were 72% male, 45% cardiologists, 15% endocrinologists, and 21% primary care physicians. Majority of PRS results (93%) were returned via an online patient portal. Increased proportion of specialist referrals, lab testing, and cardiac testing was observed in high-risk PRS patients (Table 1).Conclusion: This study provides real-world insights into adoption of PRS testing in clinical care. Findings suggest PRS may influence clinical decision-making, guide early intervention and personalize management.
M. Raviv: None. S. Mwanda: None. A. Ashworth: None. A. Epshteyn: None. A. Grewal: None. A. Joseph: None. A. Kondilis: None. A. Qamar: None. Z. Shi: None. A. Shon: None. O. Siddiqui: None. J. Wilson: None. J. Xu: Board Member; GoPath Diagnostics, GenomicMD. L.K. Billings: Advisory Panel; Novo Nordisk, Eli Lilly and Company, Sanofi. Consultant; Dexcom, Inc. Advisory Panel; Bayer Pharmaceuticals, Inc. Consultant; Xeris Pharmaceuticals, Inc. Advisory Panel; Amgen Inc. Consultant; Pfizer Inc.
Source link
Leave a Reply